China Liver Cancer Therapeutics Market Report 2022 to 2030

China Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the China liver cancer therapeutics market will reach a value of $953.6 Mn from $235.5 Mn in 2022, growing at a CAGR of 19.1% during 2022-30. The liver cancer therapeutics market in China is dominated by a few domestic pharmaceutical companies such as BeiGene, Chi-Med, and Jiangsu HengRui Medicine. The liver cancer therapeutics market in China is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10CNPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Vishwa Modhia

Buy Now

China Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the China liver cancer therapeutics market will reach a value of $953.6 Mn from $235.5 Mn in 2022, growing at a CAGR of 19.1% during 2022-30.

China is an upper middle-income developing country in East Asia bordering the East China Sea, Korea Bay, and the South China Sea. Liver or Hepatocellular cancers account for around 30% of all gastrointestinal cancers diagnosed in China as a result of alcohol misuse. In China, where liver cancer is one of the top causes of cancer-related fatalities, it is a serious public health concern. In China, liver cancer is often treated with a combination of therapies including surgery, radiation therapy, chemotherapy, targeted therapy, and traditional Chinese medicine.

According to the latest WHO data published in 2020 Liver Cancer Deaths in China reached 180,952 or 1.88% of total deaths. The age-adjusted Death Rate is 9.30 per 100,000 of the population ranks China 33^rd in the world. China's new Liver cancer cases and deaths account for about half of the global total, and its 5- year survival rate is only 14%. China's government spends 5.6 % of its GDP on healthcare in 2020.

china liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

Traditional Chinese medicine (TCM), in addition to Western medicine, is employed in the treatment of liver cancer in China. TCM employs herbal medicine, acupuncture, and other therapies to enhance health and restore balance. Several herbal treatments, including Curcumin and Ganoderma, are utilized in TCM to treat liver cancer. Liver cancer, commonly known as hepatocellular carcinoma (HCC), is a major health concern in China, where it is the second most frequent type of cancer. Manufacturing is still highly valued in China, while the services sector is growing as a result of e-commerce trends.

Market Restraints

While China has a robust research infrastructure, there may be a lack of focus on specific liver cancer subtypes that are more common in other parts of the world. As a result, funding, and resources for research into these subtypes may be limited. Access to healthcare in China can be limited in some areas, particularly in rural areas.

Competitive Landscape

Key Players

BeiGene - BeiGene is a Chinese biopharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as tislelizumab and pamiparib
Chi-Med - Chi-Med is a Chinese biopharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as surufatinib (Sulanda) and fruquintinib
Jiangsu HengRui Medicine - Jiangsu HengRui Medicine is a Chinese pharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as camrelizumab
Innovent Biologics - Innovent Biologics is a Chinese biopharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as sintilimab
LianBio - LianBio is a Chinese-American biopharmaceutical company that develops and produces a range of medicines, including treatments for liver cancer such as pegbelfermin

Recent Notable Updates

December 2022: BeiGene is a multinational biotechnology corporation. The company announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the New Indication Marketing Authorization Application for tislelizumab (tislelizumab) for the treatment of patients with first-line unresectable or metastatic hepatocellular carcinoma (HCC).

Healthcare Policies and Reimbursement Scenarios

In China, the regulation of liver cancer therapeutics is overseen by the National Medical Products Administration (NMPA), which is responsible for evaluating the safety, efficacy, and quality of all medicines and medical devices, including those used for the treatment of liver cancer. The public health insurance system is administered by the National Healthcare Security Administration (NHSA) and provides coverage for a range of liver cancer therapeutics, including chemotherapy, targeted therapy, and immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.